JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 1993; 22:1320-1326
© 1993 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vybiral, T
Right arrow Articles by Pratt, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vybiral, T
Right arrow Articles by Pratt, C.

Effects of low dose transdermal scopolamine on heart rate variability in acute myocardial infarction

T Vybiral, DH Glaeser, G Morris, KR Hess, K Yang, M Francis, and CM Pratt

Department of Medicine, Baylor College of Medicine, Houston, Texas.

OBJECTIVES. We hypothesized that by enhancing parasympathetic activity, low dose transdermal scopolamine would increase heart rate variability after myocardial infarction. BACKGROUND. Low heart rate variability is associated with increased mortality after acute myocardial infarction. METHODS. Conventional time domain heart rate variability was measured from 24-h Holter recordings of 61 consecutive male patients (mean age 58 +/- 10 years, left ventricular ejection fraction 44.7 +/- 15.5%) 6 days (median) after acute myocardial infarction. Patients were then randomly assigned to wear one patch of transdermal scopolamine or a matching placebo patch for 24 h, during which their 24-h heart rate variability was remeasured. RESULTS. Compared with placebo, transdermal scopolamine caused a significant increase in time domain measures of 24-h heart rate variability by 26% to 35% above baseline. Transdermal scopolamine was well tolerated. CONCLUSIONS. Low dose transdermal scopolamine safely increases cardiac parasympathetic activity and short-term heart rate variability after acute myocardial infarction. Whether the effect of transdermal scopolamine on heart rate variability is a reasonable surrogate for improvement of long-term morbidity and mortality requires an appropriate designed investigation.


This article has been cited by other articles:


Home page
 J. Appl. Physiol.Home page
G. E. Billman and M. Kukielka
Effects of endurance exercise training on heart rate variability and susceptibility to sudden cardiac death: protection is not due to enhanced cardiac vagal regulation
J Appl Physiol, March 1, 2006; 100(3): 896 - 906.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. Selman
Scopolamine? Reply
J. Am. Coll. Cardiol., February 20, 2002; 39(4): 744 - 745.
[Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
G. E. Billman
Aerobic exercise conditioning: a nonpharmacological antiarrhythmic intervention
J Appl Physiol, February 1, 2002; 92(2): 446 - 454.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N. Singh, D. Mironov, P. W. Armstrong, A. M. Ross, and A. Langer
Heart Rate Variability Assessment Early After Acute Myocardial Infarction : Pathophysiological and Prognostic Correlates
Circulation, April 1, 1996; 93(7): 1388 - 1395.
[Abstract] [Full Text]

Home page
 CirculationHome page
T. F. o. t. E. S. o. C. t. N. A. S. o. P. Electrophysiology
Heart Rate Variability : Standards of Measurement, Physiological Interpretation, and Clinical Use
Circulation, March 1, 1996; 93(5): 1043 - 1065.
[Full Text]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1993 by the American College of Cardiology Foundation.